0QAH.LSE Merck & Company Inc
- Market cap
- USD 373B
- P/E
- 21.4x
- P/B
- 8.81x
- ROE
- -
- Dividend yield
- 2.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0QAH.LSE undervalued?
Graham number0QAH.LSE trades 189.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Merck & Company Inc fundamental analysis
No fundamental analysis for Merck & Company Inc yet.
Merck & Company Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccine…
Full company profileMerck & Company Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Merck & Company Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 39.8B | 40.1B | 42.3B | 39.1B | 41.5B | 48.7B | 59.3B | 60.1B | 64.2B | 65.0B | 67.9B |
| Gross Profit | 26.3B | 27.4B | 28.9B | 28.1B | 29.5B | 35.2B | 42.1B | 44.0B | 49.0B | 53.0B | 51.5B |
| Operating Income | 10.1B | 8.00B | 10.1B | 10.6B | 7.74B | 13.9B | 20.5B | 4.57B | 20.2B | 26.8B | 6.57B |
| EBITDA | 15.3B | 12.6B | 14.6B | 13.7B | 11.0B | 17.0B | 24.3B | 6.91B | 25.7B | 29.3B | 11.1B |
| Net Income | 3.92B | 2.39B | 6.22B | 5.69B | 4.52B | 12.3B | 14.5B | 365M | 17.1B | 18.3B | -680M |
| EPS | 1.41 | 0.87 | 2.32 | 2.21 | 1.78 | 4.86 | 5.71 | 0.14 | 6.74 | 7.28 | -0.27 |
| Balance Sheet | |||||||||||
| Total Assets | 95.4B | 87.9B | 82.6B | 84.4B | 91.6B | 106B | 109B | 107B | 117B | 137B | - |
| Total Liabilities | 55.1B | 53.3B | 55.8B | 58.4B | 66.2B | 67.4B | 63.1B | 69.0B | 70.7B | 84.2B | - |
| Shareholders' Equity | 40.1B | 34.3B | 26.7B | 25.9B | 25.3B | 38.2B | 46.0B | 37.6B | 46.3B | 52.6B | - |
| Cash & Short-term Investments | 14.3B | 8.50B | 8.86B | 10.5B | 8.05B | 8.10B | 13.2B | 7.09B | 13.7B | 14.6B | - |
| Total Debt | 24.8B | 24.4B | 25.1B | 27.1B | 33.1B | 34.3B | 31.7B | 36.0B | 37.1B | 49.3B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 10.4B | 6.45B | 10.9B | 13.4B | 10.2B | 14.1B | 19.1B | 13.0B | 21.5B | 16.5B | 18.6B |
| Capital Expenditure | 1.61B | 1.89B | 2.62B | 3.37B | 4.43B | 4.45B | 4.39B | 3.86B | 3.37B | 4.11B | 3.77B |
| Free Cash Flow | 8.76B | 4.56B | 8.31B | 10.1B | 5.81B | 9.66B | 14.7B | 9.14B | 18.1B | 12.4B | 14.8B |
| Ratios | |||||||||||
| ROE | 9.8% | 7.0% | 23.3% | 22.0% | 17.8% | 32.3% | 31.6% | 1.0% | 37.0% | 34.7% | - |
| ROA | 4.1% | 2.7% | 7.5% | 6.7% | 4.9% | 11.7% | 13.3% | 0.3% | 14.6% | 13.3% | - |
| Net Profit Margin | 9.8% | 6.0% | 14.7% | 14.5% | 10.9% | 25.3% | 24.5% | 0.6% | 26.7% | 28.1% | -1.0% |
| Debt to Equity | 0.62x | 0.71x | 0.94x | 1.05x | 1.31x | 0.90x | 0.69x | 0.96x | 0.80x | 0.94x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Merck & Company Inc dividends
- Dividend yield
- 2.19%
- Forward dividend
- 3.24 USD
- Payout ratio
- 44.8%
- Ex-dividend date
- Jun 16, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 8.18B | 3.26 | 44.8% |
| 2024 | USD 7.84B | 3.09 | 45.8% |
| 2023 | USD 7.45B | 2.86 | 2,039.7% |
| 2022 | USD 7.01B | 2.76 | 48.3% |
| 2021 | USD 6.61B | 2.60 | 53.5% |
| 2020 | USD 6.22B | 2.45 | 137.5% |
| 2019 | USD 5.70B | 2.21 | 100.1% |
| 2018 | USD 5.17B | 1.93 | 83.2% |
| 2017 | EUR 5.17B | 1.88 | 215.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Merck & Company Inc
- Insiders 0.06%
- Institutions 82.65%
- Public & others 17.30%
- Shares outstanding 2.51B
- Free float 2.46B
Merck & Company Inc company profile
- Company name
- Merck & Company Inc
- Ticker
- 0QAH.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 73,000
- Fiscal year end
- December
- Address
- 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
- Phone
- 908 740 4000
- Website
- merck.com
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Company Inc management
10- Mr. Robert M. Davis J.D.Chairman, President & CEO · born 1967
- Ms. Caroline A. LitchfieldExecutive VP & CFO · born 1969
- Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel · born 1978
- Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories · born 1963
- Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller · born 1967
- Mr. Gaurav K. GuptaExecutive Vice President and Chief Information & Digital Officer
- Mr. Peter DannenbaumVice President of Investor Relations
- Mr. Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications · born 1966
- Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer · born 1976
- Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health · born 1963